Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy
This paper examines the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: minimum efficacy standards (MES) and a mix of minimum efficacy standards and price control mechanisms (MES+PC). Through a simple model of adverse selection we model the interaction between firms, heterogeneous buyers and the regulator. The theoretical analysis provides two results. First, an MES regime provides greater incentives to produce high quality drugs. Second, an MES+PC mix reduces the difference in price between the highest and lowest quality drugs on the market. The empirical analysis based on US and Italian data corroborates these results.
This paper was revised on December 5, 2011
Document Object Identifier (DOI): 10.3386/w14567
Published: Pharmaceutical industry, drug quality and regulation.Evidence from US and Italy Journal Article Authors Vincenzo Atella - Stanford University Jay Bhattacharya - Stanford University Carbonari, L. Published by Health Service Research, Vol. 47 no. 1 pt 1, page(s) 293-308 February 2012
Users who downloaded this paper also downloaded* these: